Pluri Inc.PLUREarnings & Financial Report
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
PLUR Q2 2026 Key Financial Metrics
Revenue
$198.0K
Gross Profit
$86.0K
Operating Profit
$-6.5M
Net Profit
$-6.5M
Gross Margin
43.4%
Operating Margin
-3285.9%
Net Margin
-3304.5%
YoY Growth
7.0%
EPS
$-0.71
Financial Flow
Pluri Inc. Q2 2026 Financial Summary
Pluri Inc. reported revenue of $198.0K for Q2 2026, with a net profit of $-6.5M (-3304.5% margin). Cost of goods sold was $112.0K, operating expenses totaled $6.6M.
Key Financial Metrics
| Total Revenue | $198.0K |
|---|---|
| Net Profit | $-6.5M |
| Gross Margin | 43.4% |
| Operating Margin | -3285.9% |
| Report Period | Q2 2026 |
Pluri Inc. Annual Revenue by Year
Pluri Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.3M |
| 2024 | $326.0K |
| 2023 | $287.0K |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71000 | $96000 | $326000 | $185000 | $427000 | $398000 | $316000 | $198000 |
| YoY Growth | -18.4% | -13.5% | 503.7% | 76.2% | 501.4% | 314.6% | -3.1% | 7.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $36.4M | $39.5M | $35.4M | $30.9M | $37.4M | $38.7M | $33.7M | $30.6M |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $-356000 | $96000 | $-5.3M | $-8.0M | $-4.5M | $-6.8M | $-11.4M | $-14.6M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.2M | $-4.3M | $-4.1M | $-4.6M | $-4.3M | $-5.2M | $-5.4M | $-5.2M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M